KIT P551_E554delPMYE

CI-VAR-00003362Explore in graph →CIViC 1497

Curated evidence

Evidence by cancer (5 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–5 of 5 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor5
KIT P551_E554delPMYE	Ponatinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID4125 In an in vitro study, an IL3 independent Ba/F3 cell line expressing KIT P551_E554delPMYE primary activating mutation demonstrated sensitivity to ponatinib treatment (IC50: 15nM). IC50 was determined b… (full text at CIViC) PMID 25239608 · Garner et al., 2014 · Open in CIViC	civic
KIT P551_E554delPMYE	Sunitinib	Predictive	B	Supports Resistance	—	submitted	EID4454 In a prospective study of 137 gastrointestinal stromal tumor patients who failed imatinib treatment, tumors with KIT exon 11 mutations (52/89) treated with sunitinib were associated with shorter prog… (full text at CIViC) PMID 22439647 · Rutkowski et al., 2012 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.